Two studies recently reported on Hulio, the adalimumab biosimilar marketed and developed by Mylan and its partner Fujifilm Kyowa Kirin Biologics.
Two studies recently reported on the adalimumab biosimilar marketed and developed by Mylan and its partner Fujifilm Kyowa Kirin Biologics, saying Hulio (named FKB327 during development) is equivalent to AbbVie’s blockbuster adalimumab (Humira) for treating rheumatoid arthritis, as well as having comparable bioavailability among delivery methods.
Adalimumab, an inhibitor of tumor necrosis factor alpha (TNF-ɑ), is typically prescribed for rheumatoid arthritis and additional conditions including psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.
A randomized, phase 3, double-blind study of 24-week duration (Period I) followed by an open-label period (Period II) found FKB327 was equivalent to reference product Humira in clinical efficacy and demonstrated comparable safety and immunogenicity in patients with moderate-to-severe rheumatoid arthritis also taking methotrexate.1
FKB327 contains adalimumab but includes different excipients. Preclinical studies showed FKB327 and originator adalimumab are comparable with respect to binding to the target antigens and for inducing apoptosis and cellular cytotoxicity. A subsequent phase 1 clinical study of FKB327 and adalimumab demonstrated comparable pharmacokinetic, safety, and immunogenicity profiles.
The primary endpoint of Period I was ACR20 (American College of Rheumatology) response rate. At 24 weeks of treatment, 74.1% of patients on FKB327 and 75.7% of patients on adalimumab showed an ACR20 response. ACR50 and ACR70 response rates were also similar in the 2 groups.
During the open-label phase of the study (Period II), patients were re-randomized, with two-thirds remaining on the same treatment and the other third switching treatments. No significant differences in ACR20, ACR50, ACR70 response rates were seen between the 4 drug sequence groups at 54 weeks or at interim points throughout Periods I and II. Immunogenicity and rates of adverse events were also comparable between groups.
The second trial was an open-label study which assessed bioavailability of a single subcutaneous dose of FKB327 in 195 healthy subjects by 3 different delivery methods: prefilled syringe, auto-injector, and vial with disposable syringe. This study reported pharmacokinetic parameters, safety, immunogenicity were similar in the 3 delivery methods, suggesting these delivery methods could be used interchangeably in clinical practice.2
In 2018, Humira accounted for 61% of AbbVie’s revenues, but that percentage began falling last year as adalimumab competitors in Europe, such as Hulio, took hold. In the United States, however, Humira will not face a biosimilar challenger until 2023.
References
1. Genovese MC, Glover J, Greenwald M, et al. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension [published online December 12, 2019]. Arthritis Res Ther. doi:10.1186/s13075-019-2046-0
2. Bush J, Kawakami K, Muniz R. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects [published online December 30, 2019]. BMC Pharmacol Toxicol. doi:10.1186/s40360-019-0376-9.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study
September 28th 2024A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford University School of Medicine, gave an overview of patient-reported outcomes (PROs) in the VOLTAIRE-RA trial.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.